AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Gastric emptying and related symptoms in patients treated with buspirone, amitriptyline or clebopride: a "real world" study by ¹³C-octanoic acid breath test

This is the author's manuscript

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/1650092> since 2017-11-20T15:30:38Z

Published version:

DOI:10.23736/S0026-4806.17.05320-4

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

UNIVERSITÀ DEGLI STUDI DI TORINO

This is an author version of the contribution published on:

Questa è la versione dell'autore dell'opera:

[Minerva Medica, 2017, 10.23736/S0026-4806.17.05320-4]

ovvero [Caviglia GP, Sguazzini C, Cisaro' F, Ribaldone DG, Rosso C, Fagoonee S, Smedile A, Saracco GM, Astegiano M, Pellicano R, ed. Minerva Medica, 2017, pagg.1-7]

The definitive version is available at:

La versione definitiva è disponibile alla URL:

[<https://www.minervamedica.it/it/riviste/minerva-medica/index.php>]

Gastric emptying and related symptoms in patients treated with buspirone, amitriptyline or clebopride: a “real world” study by ¹³C-octanoic acid breath test

G. P. CAVIGLIA¹, C. SGUAZZINI², F. CISARO², D. G. RIBALDONE², C. ROSSO¹, S. FAGOONEE³, A. SMEDILE^{1,2}, G. M. SARACCO^{1,2}, M. ASTEGIANO², R. PELLICANO²

¹Department of Medical Sciences, University of Turin, Turin, Italy

²Unit of Gastroenterology and Hepatology, Città della Salute e della Scienza - Molinette Hospital, Turin, Italy

³Institute for Biostructures and Bioimages CNR c/o Molecular Biotechnology Center, University of Turin, Turin, Italy

Corresponding author: Gian Paolo Caviglia, Department of Medical Sciences, University of Turin, Via San Massimo 24, Turin 10100, Italy. Tel: +39 (0)11 633 3532; Fax: +39 (0)11 633 3976; e-mail: caviglia.giampi@libero.it

Conflict of interest statement: The authors certify that there is no conflict of interest with any financial organization regarding the material discussed in the manuscript.

This work was not supported by grants.

Running title: Functional dyspepsia and OBT

Abstract

BACKGROUND: Gastric motility is a key-factor in the pathogenesis of functional dyspepsia (FD).

¹³C-octanoic acid breath test (OBT) is a tool used for measuring gastric emptying time in clinical setting. We aimed to investigate the variation in FD symptoms and OBT parameters before and after treatment with buspirone, amitriptyline or clobopride.

METHODS: Between Jan-2007 and Dec-2014, we enrolled 59 patients with FD unresponsive to first-line therapy with proton pump inhibitors and/or domperidone that underwent OBT before and after 3 months of buspirone (n=32), amitriptyline (n=16) or clobopride (n=11) treatment.

RESULTS: Early satiation severity was positively correlated with gastric half emptying time ($t_{1/2}$) ($r=0.3789$, $p=0.003$) and gastric lag phase ($r=0.3371$, $p=0.011$), and negatively correlated with gastric emptying coefficient ($r=-0.3231$, $p=0.015$). A reduction in $t_{1/2}$ measurement in association to post-prandial fullness, and early satiation severity improvement was observed ($p=0.009$, $p=0.005$ and $p<0.001$, respectively). Patients treated with buspirone obtained both a decrease in $t_{1/2}$ ($p=0.005$) and an amelioration in early satiation ($p=0.001$). Patients under amitriptyline treatment experienced an improvement in post-prandial fullness ($p=0.046$), whereas no variation was reported in patients treated with clobopride.

CONCLUSIONS: Patients with FD, non-responders to first-line therapy and reporting meal-related discomfort, may benefit from buspirone or amitriptyline-based therapies.

Key words: Breath test - Functional dyspepsia - Gastrointestinal motility

Dyspepsia is a common disorder characterized by upper abdominal discomfort or pain and meal-related symptoms, with a notable impact on quality of life and sense of well-being of affected subjects.¹ In the clinical context, a key issue is the accurate identification of patients with dyspepsia who require further investigation to rule out serious underlying structural diseases.² Despite a certain degree of overlapping features, according to Rome IV criteria, functional dyspepsia (FD) is defined as the predominant presence of one or more symptoms including bothersome postprandial fullness or early satiation (post-prandial distress syndrome), epigastric pain (epigastric pain syndrome) or epigastric burning, occurring for the last 3 months with the onset occurring at least 6 months prior to diagnosis, in absence of evident structural disease.^{3,4} While the global prevalence of FD is estimated to be 10-30% worldwide,³ in Italy, in the general population, it reaches to 11% with unemployment, divorce and smoking, but not *Helicobacter pylori* (*H. pylori*) infection, being the main cause associated with an increased risk.⁵

The pathogenesis of FD is likely multifactorial and still unclear; however, impaired gastrointestinal motility with delayed gastric emptying, impaired gastric accommodation after ingestion of a meal, and gastric and duodenal hypersensitivity to distension and intraluminal contents, seem to play a role in a substantial group of patients.⁶ Although the gold standard for the diagnosis of delayed gastric emptying is gastric scintigraphy,^{7,8} this method has some limitations mainly due to the use of radioactive material. As a consequence, it cannot be performed in pregnant women and may raise some safety concerns in breast-feeding women and young patients. Furthermore, scintigraphy is a relatively expensive procedure not always available outside specialist centers. Therefore, ¹³C-octanoic acid breath test (OBT) has been proposed as a reliable alternative indirect method for measuring gastric emptying of solids.⁹⁻¹¹

Currently, there is no treatment with established efficacy for FD. In the primary care setting, the first-line therapeutic approach is often represented by antacids, proton pump inhibitors (PPI) and/or prokinetic drugs, such as domperidone, according to predominant symptom.¹ Antidepressant, anxiolytic and other prokinetic drugs should be taken into account in patients non-responders to first-line treatment.

The aim of this study was to investigate, in a specialistic setting, the association between FD symptoms and OBT parameters before and after treatment with buspirone, amitriptyline or clobopride, in patients unresponsive to first-line treatment.

METHODS

Patients

The study was conducted at the third-level Outpatient Clinic of Gastroenterology, Molinette and San Giovanni Antica Sede Hospital, Turin, Italy. The flow chart of the study is depicted in Figure 1. From a total of 870 patients with upper abdominal complaints, who underwent OBT for gastric emptying measurement, between January 2007 and December 2014, we retrospectively enrolled 59 patients with FD diagnosed according to Rome III criteria and unresponsive to first-line therapy with PPI and/or domperidone.³ To meet the criteria for the definition of FD, patients had to have undergone upper gastrointestinal endoscopy. All included subjects had repeated OBT assessment after 12 weeks of second-line treatment. Seven patients reported a previous history of *H. pylori* infection, with therapy taken more than 6 months before OBT assessment, and eradication confirmed by urea breath test. The remaining patients had negativity *ab initio* for this infection. Data regarding dyspeptic symptoms (bothersome postprandial fullness, early satiation, epigastric pain and epigastric burning) were collected before and after treatment, and scored according to severity (0 = absent, 1 = mild, when the

symptom could not be ignored, but did not influence daily activities, 2 = severe, when the symptom influenced daily activities).¹³

Overall, 32 patients were orally treated for 12 weeks with buspirone 10 mg twice daily, 16 patients with amitriptyline 4.5 mg twice daily for the first 2 days followed by 7.5 mg twice daily for the remaining treatment period, and 11 patients with clobopride 5 mg twice daily before meals for the entire period.

The study protocol was conformed to the Declaration of Helsinki guidelines. Data were managed with respect of patients' privacy. All patients gave their written informed consent prior to treatment.

¹³C-octanoic acid breath test

Gastric emptying rate was determined by OBT. All patients were fasted for 12 hours prior to undergoing breath test. Weight and height were assessed, and 2 basal breath samples were collected before meal. The test meal consisted in a muffin (EXPIROGer[®], SOFAR, Italy) with a total caloric value of 378 kcal (57 g carbohydrate, 14 g fat, 6 g protein and 100 mg of ¹³C-Octanoic acid without gluten, glucose and lactose) and 150 mL of natural water.^{9, 11} Afterwards, breath samples were collected in 10 mL plastic tubes every 15 minutes up to a 4-hours period. The ratio of ¹³CO to ¹²CO was measured in each breath sample by isotope ratio mass-spectrometer (QuinTron Instrument Company, USA).¹⁴ The parameters calculated were gastric half-emptying time ($t_{1/2}$), defined as the time needed by the stomach to metabolize and excrete the half of ¹³C-labeled substrate, gastric lag phase (t_{lag}), defined as the required time to reach the maximum emptying peak of the ¹³C-labeled substrate, and gastric emptying coefficient (GEC), an index that accounts for the rates of both

appearance and disappearance of the label in breath.^{15, 16} According to the supplier's instructions, delayed gastric emptying was defined as $t_{1/2}$ of more than 120 minutes.

Statistical Analysis

Continuous variables were expressed as median and 95% confidence interval (CI) of the median. Test for normal distribution was performed by D'Agostino-Pearson normality test. Kruskal-Wallis test and chi-squared test were performed to compare basal continuous and categorical variables, respectively. Pearson's correlation coefficient (r) was used to measure the degree of association between two continuous variables. Wilcoxon test and Kendall's coefficient of concordance were used to compare paired continuous and categorical variables before and after treatment, respectively.

For all analyses, a $p < 0.05$ was considered significant. All statistical analyses were performed by SPSS software version 22.0 (IBM SPSS Statistics for Windows, Chicago, IL).

RESULTS

Basal demographical, clinical data and OBT parameters of the 59 enrolled patients are reported in Table I. Median age was 49.9 years and the majority of patients were females (79.7%). Age distribution was significantly different according to treatment regimen ($p = 0.034$). In particular, patients treated with buspirone were older than those treated with clobopride (54.1 years vs. 37.2 years, $p = 0.011$). Age was positively correlated with early satiation severity ($r = 0.2633$, 95% CI: 0.0077 - 0.4866; $p = 0.044$) and with t_{lag} values ($r = 0.2680$, 95% CI: 0.0055 - 0.4959; $p = 0.046$) and negatively correlated with post-prandial fullness ($r = -0.2809$, 95% CI: -0.5009 - -0.0267; $p = 0.031$). In addition, a trend towards a correlation between age and $t_{1/2}$ ($r = 0.2458$, 95% CI: -0.0110 - 0.4722; $p = 0.061$) was observed. Body mass index (BMI) was neither associated with clinical and demographical data nor

with OBT parameters. No difference was found in basal OBT parameters according to treatment subgroups ($t_{1/2}$, $p=0.438$; t_{lag} , $p=0.260$; and GEC, $p=0.416$). Symptoms severity distribution was significantly different, according to treatment regimen, for early satiation ($p=0.006$) and a trend could be denoted for epigastric pain ($p=0.073$), whereas no differences were found for post-prandial fullness and for epigastric burning. In particular, 16 out of 20 patients with severe early satiation, and 7 out of 9 with mild early satiation, respectively, were treated with buspirone. In addition, early satiation severity was positively correlated with $t_{1/2}$ values ($r=0.3789$, 95% CI: 0.1360 - 0.5788; $p=0.003$) and t_{lag} values ($r=0.3371$, 95% CI: 0.0815 - 0.5512; $p=0.011$) and negatively correlated with GEC ($r= -0.3231$, 95% CI: -0.5401 - -0.0658; $p=0.015$).

All patients underwent a second OBT assessment after 90 ± 15 days of treatment. Overall, a significant reduction of $t_{1/2}$ measurement associated to a significant improvement of post-prandial fullness and early satiation severity were observed ($p=0.009$, $p=0.005$ and $p<0.001$, respectively) (Table II and Table III). According to treatment regimen, patients that underwent buspirone-based therapy obtained a significant reduction in $t_{1/2}$ values ($p=0.005$) and a significant amelioration in early satiation ($p=0.001$). In addition, a trend toward t_{lag} and GEC amelioration values was found ($p=0.085$ and $p=0.060$, respectively). Patients treated with amitriptyline experienced a significant improvement in post-prandial fullness ($p=0.046$), whereas no significant variation was reported in patients under clobopride therapy in OBT parameters and in symptoms severity.

Three out of 59 enrolled patients reported mild side effects: one under buspirone treatment experienced dizziness whereas other two treated with amitriptyline reported dysgeusia and asthenia, respectively. Nevertheless, none of them stopped treatment.

DISCUSSION

This retrospective study, conducted in the real world, explored the effect of buspirone, amitriptyline and clobopride treatment on symptoms severity and OBT parameters in patients with FD diagnosis.

In agreement with previous observations,¹⁷ we found a weak correlation between older age and worse OBT parameters, particularly with t_{lag} ($r=0.2680$; $p=0.046$). In addition, age was directly associated with early satiety severity, and had an inverse relationship with the prolonged fullness. It has been hypothesized that older patients have a slow gastric motility due to the decreased number of Cajal cells, a nervous-like cell type involved in electrical rhythmicity generation in smooth muscles.¹⁸

In contrast to other data, BMI was neither correlated with symptoms severity nor with OBT parameters.¹⁹ However, our cohort included normal-weight patients (BMI was in the normal range of 18.0-24.9 Kg/cm²), therefore we could not assess the association between symptoms and OBT parameters in over-weight or obese subjects.

Currently, available data regarding correlation between symptoms severity and OBT parameters are controversial.²⁰ In the present study, we found a significant association between early satiation and all OBT parameters, suggesting that alterations in gastric motility may underlie FD manifestations.

After 3 months of therapy, we found a significant improvement of post-prandial fullness ($p=0.005$) and early satiation severity ($p<0.001$) together with a significant $t_{1/2}$ reduction ($p=0.009$). In particular, buspirone led to early satiation and $t_{1/2}$ improvement ($p=0.001$ and $p=0.005$, respectively), and amitriptyline in post-prandial fullness amelioration ($p=0.046$), whereas no significant variation was observed in patients treated with clobopride. As reported by Tack *et al*, in a prospective randomized trial, buspirone may be most beneficial for patients with meal-related dyspepsia without affecting symptoms characteristics of epigastric pain syndrome. However, the authors did not observe any concomitant significant change in solid emptying time assessed by breath test.²¹ In contrast to our

results, Talley *et al*, in a recent multicenter trial, found that amitriptyline appeared to induce benefit mainly in FD patients with ulcer-like pain.²² Probably, the low number of patients enrolled in our study may result in different findings. Regarding clebopride, the absence of clinical relief emphasized by no variation in OBT parameters could be explained by the feature of included patients already unresponsive to first-line therapy with domperidone. Hence, the use of another prokinetic drug, as rescue treatment, did not led to any symptom improvement.

The main limitation of our study is represented by its retrospective design. All patients were recruited between 2007 and 2014, thus FD diagnosis was set according to Rome III criteria. However, in the setting of FD, only minor changes have been introduced following Rome IV classification. Therefore, we think that patients' classification can be considered valid. In addition, patients' enrolment did not allow us to evaluate symptoms severity by validated scores, such as dyspepsia severity score or visual analogue scale. To clarify the allocation of patients to treatment, it should be highlighted that according to literature, our choice is usually to plan a rescue therapy on the basis of the prevalent symptom,³ using buspirone in case of meal-related symptoms and amitriptyline when an associated psychological disorder (anxiety, depression or both) can be recognized. Finally, clebopride is used in absence of these conditions or in case of patient's refusal to other treatments. On the other hand, the low number of patient treated with amitriptyline and clebopride may have underpowered the results obtained in our study. In fact, patients treated with amitriptyline experienced an improvement for both symptoms severity and OBT parameters without reaching a statistical significance. However, to our knowledge, this is the largest cohort of patients with FD treated with buspirone that underwent OBT before and after treatment. Moreover, this population reflects what happens in real clinical practice.

An unsolved issue remains the search and the treatment for *H. pylori* infection in FD patients. Although worldwide data are heterogeneous, both in terms of prevalence and post-eradication benefit,²³⁻²⁵ the European guidelines state that bacterial cure produced long-term benefits in one of 12 patients with *H. pylori* infection and FD, and that this is better than any other treatment.²⁶ Considering that the choice of the more appropriate treatment should be based on local antibiotic usage, documented antibiotic resistance and outcome data,²⁷ before starting a long-term treatment, as those reported in our study, the search for the bacterium could be performed. On the other hand, it has been reported that there is no relationship between *H. pylori* infection and gastric emptying in patients with FD.²⁸

In conclusion, we found that FD was associated with gastric motility abnormalities detectable by OBT. In addition, there was a relationship between symptoms amelioration and the decrease in gastric solid emptying time. Patients non-responders to first-line therapy with PPI and/or domperidone, reporting meal-related discomfort, may benefit from buspirone or amitriptyline-based therapy with no relevant side effects.

REFERENCES

1. Bytzer P, Talley NJ. Dyspepsia. *Ann Intern Med* 2001;134:815-22.
2. Talley NJ, Ford AC. Functional Dyspepsia. *New Engl J Med* 2015;373:1853-63.
3. Stanghellini V, Chan FKL, Hasler WL, Malagelada JR, Suzuki H, Tack J *et al.* Gastroduodenal disorders. *Gastroenterology* 2016;150:1380-92.
4. De Bortoli N, Natali V, Melissari S, Simonetti N, Tapete G, Marchi S. Overlap of GERD and gastrointestinal functional disorders. *Minerva Gastroenterol Dietol* 2017; in press. doi: 10.23736/S1121-421X.17.02398-4.
5. Zagari RM, Law GR, Fuccio L, Cennamo V, Gilthorpe MS, Forman D *et al.* Epidemiology of functional dyspepsia and subgroups in the Italian general population: an endoscopic study. *Gastroenterology* 2010;38:1302-11.
6. Carbone F, Tack J. Gastroduodenal mechanism underlying functional gastric disorders. *Dig Dis* 2014;32:222-9.
7. Bruno G, Lopetuso LR, Ianiro G, Laterza L, Gerardi V, Petito V *et al.* ¹³C-octanoic acid breath test to study gastric emptying. *European Review for Medical and Pharmacological Sciences* 2013;17:59-64.
8. Penagini R, Bravi I. The role of delayed gastric emptying and impaired oesophageal body motility. *Best Practice and Research: Clin Gastroenterol* 2010;24:831-45.
9. Ghoo YF, Maes BD, Geypens BJ, Mys G, Hiele MI, Rutgeerts PJ *et al.* Measurement of gastric emptying rate of solids by means of a carbon-labeled octanoic acid breath test. *Gastroenterology* 1993;104:1640-7.
10. Bromer MQ, Kantor SB, Wagner DA, Knight LC, Maurer AH, Parkman HP. Simultaneous measurement of gastric emptying with a simple muffin meal using [13C]octanoate breath test

- and scintigraphy in normal subjects and patients with dyspeptic symptoms. *Dig Dis Sci* 2002;47:1657-63.
11. Perri F, Bellini M, Portincasa P, Parodi A, Bonazzi P, Marzio L, Galeazzi F *et al.* (13)C-octanoic acid breath test (OBT) with a new test meal (EXPIROGer): Toward standardization for testing gastric emptying of solids. *Dig Liver Dis* 2010;42:549-53.
 12. Zala AV, Walker MM, Talley NJ. Emerging drugs for functional dyspepsia. *Expert Opin Emerg Drugs* 2012;20:221-33.
 13. Kong MF, Horowitz M, Jones KL, Wishart JM, Harding PE. Natural history of diabetic gastroparesis. *Diabetes Care* 1999;22:503-7.
 14. Punkkinen J, Konkka I, Punkkinen O, Korppi-Tommola T, Farkkila M, Koskenpato J. Measuring gastric emptying: comparison of 13C-octanoic acid breath test and scintigraphy. *Dig Dis Sci* 2006;51:262-7.
 15. Hauser B, De Schepper J, Caveliers V, Salvatore S, Salvatoni A, Vandenplas Y. Variability of the 13C-acetate breath test for gastric emptying of liquids in healthy children. *J Pediatr Gastroenterol Nutr* 2006;42:392-7.
 16. Zahn A, Langhans CD, Hoffner S, Haberkorn U, Rating D, Haass M *et al.* Measurement of gastric emptying by 13C-octanoic acid breath test versus scintigraphy in diabetics. *Z Gastroenterol* 2003;41:383-90.
 17. Bhutto A, Morley JE. The clinical significance of gastrointestinal changes with aging. *Curr Opin Clin Nutr Metab Care* 2008;11:651-60.
 18. Al-Shboul OA. The importance of interstitial cells of cajal in the gastrointestinal tract. *Saudi J Gastroenterol* 2013;19:3-15.

19. Mushref MA, Srinivasan S. Effect of high fat-diet and obesity on gastrointestinal motility. *Ann Transl Med* 2013;1:14.
20. Oustamanolakis P, Tack J. Dyspepsia: organic versus functional. *J Clin Gastroenterol* 2012;46:175-90.
21. Tack J, Janssen P, Masaoka T, Farrè R, Van Oudenhove L. Efficacy of buspirone, a fundus-relaxing drug, in patients with functional dyspepsia. *Clin Gastroenterol Hepatol* 2012;10:1239-45.
22. Talley NJ, Locke GR, Saito YA, Almazar AE, Bouras EP, Howden CW *et al.* Effect of amitriptyline and escitalopram on functional dyspepsia: a multicenter, randomized controlled study. *Gastroenterology* 2015;149:340-9.
23. Jodaki A, Sahraie A, Yasemi M, Peyman H, Yasemi MR, Hemati K. Helicobacter pylori eradication effect on patients with functional dyspepsia symptoms. *Minerva Gastroenterol Dietol* 2016;62:148-54.
24. Zullo A, Hassan C, De Francesco V, Repici A, Manta R, Tomao Annibale B *et al.* Helicobacter pylori and functional dyspepsia: an unsolved issue? *World J Gastroenterol* 2014;20:8957-63.
25. Marušić M, Dominković L, Majstorović Barać K, Gulić S, Bago J, Pezerović D. Bismuth-based quadruple therapy modified with moxifloxacin for Helicobacter pylori eradication. *Minerva Gastroenterol Dietol*. 2017 Jun;63(2):80-84.
26. Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F *et al.* European Helicobacter Study Group. Management of Helicobacter pylori infection: the Maastricht IV/Florence Consensus Report. *Gut* 2012;61:646-64.

27. Ribaldone DG, Fagoonee S, Astegiano M, Saracco G, Pellicano R. Efficacy of amoxycillin and clarithromycin-based triple therapy for *Helicobacter pylori* eradication: A 10-year trend in Turin, Italy. *Panminerva Med* 2015;57:145-6.
28. Caballero-Plasencia AM, Muros-Navarro MC, Martín-Ruiz JL, Valenzuela-Barranco M, de los Reyes-García MC, Casado-Caballero FJ *et al.* Dyspeptic symptoms and gastric emptying of solids in patients with functional dyspepsia. Role of *Helicobacter pylori* infection. *Scand J Gastroenterol* 1995;30:745-51.

Table I. *Basal characteristics of the 59 enrolled patients*

	Total	Buspirone	Amitriptyline	Clebopride	P
Patient number	59	32	16	11	
Age, years	49.9 (44.7-54.6)	54.1 (45.4-60.7)	50.6 (38.0-60.4)	37.2 (26.3-53.5)	0.034
Gender, M/F	12/47	7/25	2/14	2/9	0.613
BMI, Kg/cm ²	22.5 (21.6-23.2)	22.5 (21.5-24.7)	23.1 (20.7-24.1)	21.6 (20.5-23.6)	0.652
OBT					
• t _{1/2} , min	224 (203-338)	213 (184-327)	261 (146-422)	350 (187-569)	0.438
• t _{lag} , min	113 (94-136)	94 (81-115)	135 (81-186)	138 (79-321)	0.260
• GEC	2.5 (2.4-2.6)	2.6 (2.4-2.7)	2.5 (2.3-2.7)	2.5 (2.1-2.5)	0.416
Symptoms, absent/mild/severe					
• Postprandial fullness	32/16/11	21/8/3	7/5/4	4/3/4	0.234
• Early satiation	30/9/20	9/7/16	13/1/2	8/1/2	0.006
• Epigastric pain	42/10/7	27/2/3	8/6/2	7/2/2	0.073
• Epigastric burning	38/15/6	19/7/6	11/5/0	8/3/0	0.219

p values were calculated by Kruskal-Wallis test or by chi-squared test for continuous or categorical variables, respectively.

Abbreviations: F, female; GEC, gastric emptying coefficient; M, male; OBT, ¹³C-octanoic acid breath test.

Table II. *Comparison of symptoms severity before (T0) and after therapy (T1) with buspirone, amitriptyline and clebopride*

		T0	T1	p
Total	Symptoms, absent/mild/severe			
	• Postprandial fullness	32/16/11	35/23/1	0.005
	• Early satiation	30/9/20	34/22/3	< 0.001
	• Epigastric pain	42/10/7	44/13/2	0.052
	• Epigastric burning	38/15/6	39/18/2	0.248
Buspirone	Symptoms, absent/mild/severe			
	• Postprandial fullness	21/8/3	22/10/0	0.157
	• Early satiation	9/7/16	12/18/2	0.001
	• Epigastric pain	27/2/3	28/2/2	0.414
	• Epigastric burning	19/7/6	19/11/2	0.206
Amitriptyline	Symptoms, absent/mild/severe			
	• Postprandial fullness	7/5/4	9/6/1	0.046
	• Early satiation	13/1/2	13/3/0	0.157
	• Epigastric pain	8/6/2	9/7/0	0.180
	• Epigastric burning	11/5/0	11/5/0	1.000
Clebopride	Symptoms, absent/mild/severe			
	• Postprandial fullness	4/3/4	4/7/0	0.102
	• Early satiation	8/1/2	9/1/1	0.157
	• Epigastric pain	7/2/2	7/4/0	0.157
	• Epigastric burning	8/3/0	8/3/0	1.000

p values were calculated by Kendall test.

Table III. *Comparison of OBT parameters before (T0) and after therapy (T1) with buspirone, amitriptyline and clebopride*

		T0	T1	p
Total	OBT			
	• t _{1/2} , min	224 (203-338)	154 (130-186)	0.009
	• t _{lag} , min	113 (94-137)	81 (60-121)	0.114
	• GEC	2.5 (2.4-2.6)	2.5 (2.4-2.7)	0.307
Buspirone	OBT			
	• t _{1/2} , min	213 (184-327)	136 (123-167)	0.005
	• t _{lag} , min	94 (81-115)	62 (42-101)	0.085
	• GEC	2.6 (2.4-2.7)	2.7 (2.5-2.8)	0.060
Amitriptyline	OBT			
	• t _{1/2} , min	261 (146-422)	160 (126-252)	0.121
	• t _{lag} , min	135 (81-186)	88 (59-141)	0.217
	• GEC	2.5 (2.3-2.7)	2.4 (2.4-2.7)	0.910
Clebopride	OBT			
	• t _{1/2} , min	350 (187-569)	249 (105-867)	0.831
	• t _{lag} , min	138 (79-321)	129 (51-461)	0.492
	• GEC	2.5 (2.1-2.5)	2.2 (1.8-2.7)	0.359

p values were calculated by Wilcoxon test.

Abbreviations: GEC, gastric emptying coefficient; OBT, ¹³C-octanoic acid breath test.

Figure 1. *Flow chart of the study*

Abbreviations: FD, functional dyspepsia; OBT, ^{13}C -octanoic acid breath test.